FDA military informed consent rule back to drawing board
FDA withdraws its final rule on determining the circumstances under which informed consent can be waived for troops being given investigational drugs in combat situations. The rule would finalize a 1999 1interim final rule, which specifies that the President, and not the FDA commissioner, can make the determination (2"The Pink Sheet" Nov. 29, 1999, p. 10). FDA pulled the rule Oct. 10 after submitting it to OMB July 21...
You may also be interested in...
The Department of Defense will develop a protocol on the use of investigational drugs on military personnel that will incorporate the President's executive order and FDA's interim rule on seeking informed consent waivers. The protocol is expected by early next year.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.